Arbor Scientia Group Recognized as a Top Veeva Solutions Provider for 2025 by Pharma Tech Outlook

Arbor Scientia Group continues paving the way in medical education, combining excellence in scientific storytelling and optimization of submission processes

CARLSBAD, Calif., April 30, 2025 /PRNewswire/ -- Arbor Scientia Group has been recognized by Pharma Tech Outlook as a Top Veeva Solutions Provider 2025.

Arbor Scientia Group has been an established force in the medical education and communications industry since 2005 and has remained a small company dedicated to delivering quality medical education to support their pharmaceutical clients with the ultimate goal of improving patient lives. As master scientific storytellers, Arbor Scientia Group transforms complex medical content, from preclinical through post-launch, into clear and compelling narratives that engage, educate and inspire. By blending creativity with scientific and Veeva expertise, Arbor Scientia Group helps make traditionally cumbersome MLR review and approval processes a strategic advantage for clients.

Whether supporting emerging startups or global pharmaceutical brands, Arbor Scientia Group delivers science-backed storytelling that drives results and accelerates medical education. Their efforts have been recognized by Pharma Tech Outlook, and they have been presented with the Top Veeva Solutions Provider 2025 award, a prestigious recognition in the industry. Arbor Scientia Group has been selected after evaluation by an expert panel of C-level executives, industry thought leaders and editorial board members.

The full article published on Pharma Tech Outlook can be found at https://www.pharmatechoutlook.com/arbor-scientia-group.

About Arbor Scientia Group
Founded by internationally renowned psychiatrist and professor of psychiatry Stephen M. Stahl, M.D., Ph.D., D.Sc. (Hon.), D.Med.Sci. (Hon., Cambridge), and current CEO Richard Davis, an adult learning and communications expert, Arbor Scientia Group sets themselves apart in the agency landscape by not only executing tactics but also acting as a partner to their clients through collaborating on strategic insights pre-product launch and tailoring high-quality content to support product launches. Furthermore, Arbor Scientia Group recognizes that even the best stories or content will never reach their intended audience if the submission process is not carefully managed and optimized for efficiency. 

Active in more than 70 countries and able to carry out projects in accordance with GDPR regulations, Arbor Scientia Group proudly supports medical content and strategy, meetings and events, training and creative and digital teams across companies active in neurology, psychiatry, hematology, oncology, rare diseases, immunology, virology, cardiovascular, women's health, urology, diabetes and gastroenterology disease states. Leveraging a vast network of key opinion leaders in the industry and an in-house staff of Ph.D. medical writers, project management professionals, creative designers, editors and programmers, Arbor Scientia Group demonstrates measurable effectiveness in supporting their clients' milestones and goals with every strategy-supporting tactic created and event facilitated.

Arbor Scientia Group can be reached for inquiries at [email protected].

SOURCE Arbor Scientia Group